This paper reviews the therapeutic potential of Wharton’s jelly mesenchymal stem cells for diabetes. The authors cover both the achievements of current research and the challenges remaining before this becomes a standard treatment option.

For patients with diabetes — both type 1 and type 2 — this article provides insight into how regenerative cell therapy may one day complement traditional management.

This is a research reference from our clinical library. Approved by the Chambers Clinic Team — last reviewed May 28, 2026.